PDF(Pubmed)
Abstract：
Diffuse intrinsic pontine glioma (DIPG) was first described by Harvey Cushing, the father of modern neurosurgery, a century ago. Since then, the classification of this tumor changed significantly, as it is now part of the broader family of diffuse midline gliomas (DMGs), a heterogeneous group of tumors of midline structures encompassing the entire rostro-caudal space, from the thalamus to the spinal cord. DMGs are characterized by various epigenetic events that lead to chromatin remodeling similarities, as two decades of studies made possible by increased tissue availability showed. This new understanding of tumor (epi)biology is now driving novel clinical trials that rely on targeted agents, with finally real hopes for a change in an otherwise unforgiving prognosis. This biological discovery is being paralleled with equally exciting work in therapeutic drug delivery. Invasive and noninvasive platforms have been central to early phase clinical trials with a promising safety track record and anecdotal benefits in outcome.
摘要：
弥漫性内在脑桥胶质瘤（DIPG）首先由HarveyCushing描述，现代神经外科之父,一个世纪前.从那以后,这种肿瘤的分类发生了显著变化，因为它现在是弥漫性中线胶质瘤（DMGs）的更广泛家族的一部分，一组异质性的中线结构肿瘤，包括整个后部空间，从丘脑到脊髓.DMGs的特点是各种导致染色质重塑相似性的表观遗传事件，正如二十年的研究通过增加组织可用性而成为可能。这种对肿瘤（epi）生物学的新理解现在正在推动依赖于靶向药物的新型临床试验。最终真正希望改变否则无法原谅的预后。这一生物学发现与治疗药物递送中同样令人兴奋的工作平行。侵入性和非侵入性平台已成为早期临床试验的核心，具有有希望的安全跟踪记录和转归的传闻益处。
